Japan Iressa side-effect ruling favours AstraZeneca
This article was originally published in Scrip
The Tokyo High Court in Japan has overturned a lower court ruling in a case relating to side-effects attributed to AstraZeneca's lung cancer drug Iressa (gefitinib), finding both the government and the firm's local subsidiary not liable for damages.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.